Funding OpportunitiesIf approved, the program is potentially eligible for a Priority Review Voucher, which could bring in additional funding if monetized.

Product DevelopmentSpruce Biosciences licensed tralesinidase alfa, an enzyme replacement therapy, which has 1st to market potential.

Regulatory ApprovalThe FDA confirmed that HS-NRE is deemed to be a surrogate biomarker reasonably likely to predict clinical benefit and could serve as a basis for Accelerated Approval.

Bears Say

Capital RequirementsConcerns exist regarding Spruce Biosciences' ability to fund these programs without further shareholder dilution.

Financial ChallengesSPRB's cash balance is now less than $30M and the company is facing significant liquidity pressure.

Operational FundingThe company's cash resources are slated to fund operations only through 2025.

SPRBD FAQ

What was Spruce Biosciences’s price range in the past 12 months?

Spruce Biosciences lowest stock price was $4.32 and its highest was $45.60 in the past 12 months.

What is Spruce Biosciences’s market cap?

Spruce Biosciences’s market cap is $5.62M.

When is Spruce Biosciences’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Spruce Biosciences’s earnings last quarter?

Currently, no data Available

Is Spruce Biosciences overvalued?

According to Wall Street analysts Spruce Biosciences’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Spruce Biosciences pay dividends?

Spruce Biosciences does not currently pay dividends.

What is Spruce Biosciences’s EPS estimate?

Spruce Biosciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Spruce Biosciences have?

Spruce Biosciences has 563,084 shares outstanding.

What happened to Spruce Biosciences’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Spruce Biosciences?

Currently, no hedge funds are holding shares in SPRBD

Company Description

Spruce Biosciences

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.